Brokerages Set Progyny, Inc. (NASDAQ:PGNY) Target Price at $59.40

Progyny, Inc. (NASDAQ:PGNYGet Rating) has been given an average recommendation of “Moderate Buy” by the six research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $59.40.

A number of analysts have issued reports on PGNY shares. KeyCorp started coverage on shares of Progyny in a research note on Thursday, September 15th. They issued an “overweight” rating and a $55.00 target price for the company. TheStreet raised shares of Progyny from a “d+” rating to a “c” rating in a research report on Monday, October 24th. JPMorgan Chase & Co. dropped their price target on shares of Progyny from $78.00 to $62.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, Truist Financial assumed coverage on shares of Progyny in a research report on Wednesday, September 7th. They issued a “buy” rating and a $56.00 price target on the stock.

Insider Activity

In related news, Chairman David J. Schlanger sold 25,020 shares of the business’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $39.30, for a total transaction of $983,286.00. Following the transaction, the chairman now owns 82,548 shares of the company’s stock, valued at $3,244,136.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Peter Anevski sold 3,920 shares of the business’s stock in a transaction on Thursday, November 3rd. The shares were sold at an average price of $39.19, for a total transaction of $153,624.80. Following the transaction, the chief executive officer now owns 250,445 shares of the company’s stock, valued at $9,814,939.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman David J. Schlanger sold 25,020 shares of the business’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $39.30, for a total transaction of $983,286.00. Following the transaction, the chairman now directly owns 82,548 shares in the company, valued at approximately $3,244,136.40. The disclosure for this sale can be found here. Insiders have sold a total of 302,175 shares of company stock valued at $12,079,559 over the last 90 days. 14.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Progyny

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. TownSquare Capital LLC boosted its stake in Progyny by 13.7% during the second quarter. TownSquare Capital LLC now owns 12,367 shares of the company’s stock worth $359,000 after buying an additional 1,493 shares in the last quarter. Hardy Reed LLC acquired a new stake in Progyny during the first quarter worth $117,000. Yousif Capital Management LLC boosted its stake in Progyny by 6.7% during the second quarter. Yousif Capital Management LLC now owns 39,779 shares of the company’s stock worth $1,156,000 after buying an additional 2,515 shares in the last quarter. FDx Advisors Inc. acquired a new stake in Progyny during the second quarter worth $543,000. Finally, Ziegler Capital Management LLC acquired a new stake in Progyny during the first quarter worth $283,000. Institutional investors own 88.64% of the company’s stock.

Progyny Stock Up 1.5 %

NASDAQ PGNY opened at $33.92 on Friday. The stock has a market capitalization of $3.15 billion, a PE ratio of 80.76, a price-to-earnings-growth ratio of 5.92 and a beta of 1.65. The company has a 50 day moving average price of $39.10 and a two-hundred day moving average price of $36.05. Progyny has a 12-month low of $25.67 and a 12-month high of $60.89.

About Progyny

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

See Also

Analyst Recommendations for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.